secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2024-12-18T23:59:59+00:00
Accession:  0001640334-24-001908
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.0
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria Bioscience signs ~AUD$5.1M clinical study agreement with Novotech for GLP-1-H24-4 trial
--------------------------------------------------------------------------------

- Effective Dec 2, 2024: Novotech as CRO for DehydraTECH Cannabidiol + GLP-1 agonists in pre- and Type II Diabetes.
- Aggregate costs ~AUD$5.1 million; upfront payments ~AUD$414,600 (direct) and ~AUD$347,800 (pass-through).
- Lexaria AU can terminate the Project Agreement with or without cause upon 90 days' notice.
- Initial start-up work already completed under a separate Start-Up Agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033424001908/0001640334-24-001908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033424001908/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-24-001908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer